1. Volume 146, Issue 6, Pages 1521-1530 (December 2014)
Long-Acting Bronchodilators and Arterial Stiffness in Patients With COPD 
Jean-Louis Pepin, MD, PhD, John R. Cockcroft, MD, Dawn Midwinter, MSc, Sanjay Sharma, BSc, David B. Rubin, MD, Stefan Andreas, MD 
CHEST 
Volume 146, Issue 6, Pages (December 2014)
DOI: /chest
Copyright © 2014 The American College of Chest Physicians Terms and Conditions

2. Figure 1
Subject disposition for this study. See Results section for further detail. FF/VI = fluticasone furoate/vilanterol; TIO = tiotropium bromide.
CHEST  , DOI: ( /chest )
Copyright © 2014 The American College of Chest Physicians Terms and Conditions

3. Figure 2
LS mean change from baseline in aortic pulse wave velocity (aPWV) (m/s) (intent-to-treat population). Analysis was performed using a repeated-measures model with covariates of treatment, visit, age, sex, smoking status at screening, geographical region, baseline aPWV, and interaction terms of baseline by visit and treatment by visit. LS = least squares. See Figure 1 legend for expansion of other abbreviations.
CHEST  , DOI: ( /chest )
Copyright © 2014 The American College of Chest Physicians Terms and Conditions

4. Figure 3
Raw mean change from baseline in aortic pulse wave velocity (m/s) (intent-to-treat population). A post hoc analysis was performed using a mixed model repeated-measures for each treatment group separately. Raw mean changes from baseline data are presented graphically; however, the analysis showed that the adjusted mean difference from the last observation carried forward visit to the baseline visit for FF/VI was −0.9 m/s (P= .0024) and for TIO was −1.1 m/s (P= .0006). See Figure 1 and 2 legends for expansion of abbreviations.
CHEST  , DOI: ( /chest )
Copyright © 2014 The American College of Chest Physicians Terms and Conditions